David A. Siegel Trevi Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TRVI
# of Institutions
114Shares Held
77.6MCall Options Held
218KPut Options Held
182K-
Nea Management Company, LLC Timonium, MD11.4MShares$48.3 Million3.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.7MShares$45.3 Million2.72% of portfolio
-
Viking Global Investors LP4.4MShares$18.7 Million0.06% of portfolio
-
Rubric Capital Management LP New York, NY4.21MShares$17.9 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.15MShares$17.6 Million0.04% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $248M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...